Kissei Pharmaceutical Co., Ltd.
4547.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥23,640,000 | ¥22,191,000 | ¥22,661,000 | ¥23,203,000 |
| % Growth | 6.5% | -2.1% | -2.3% | – |
| Cost of Goods Sold | ¥12,032,000 | ¥11,111,000 | ¥11,714,000 | ¥11,483,000 |
| Gross Profit | ¥11,608,000 | ¥11,080,000 | ¥10,947,000 | ¥11,720,000 |
| % Margin | 49.1% | 49.9% | 48.3% | 50.5% |
| R&D Expenses | ¥0 | ¥0 | ¥2,794,000 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥20,554,000 | ¥8,971,000 | ¥9,411,000 | ¥9,264,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥1,000 | -¥2,794,000 | -¥1,000 |
| Operating Expenses | ¥20,554,000 | ¥8,972,000 | ¥9,411,000 | ¥9,263,000 |
| Operating Income | -¥8,946,000 | ¥2,108,000 | ¥1,536,000 | ¥2,457,000 |
| % Margin | -37.8% | 9.5% | 6.8% | 10.6% |
| Other Income/Exp. Net | ¥12,609,000 | ¥3,639,000 | ¥2,500,000 | ¥1,957,000 |
| Pre-Tax Income | ¥3,663,000 | ¥5,747,000 | ¥4,036,000 | ¥4,414,000 |
| Tax Expense | ¥305,000 | ¥1,227,000 | ¥915,000 | ¥811,000 |
| Net Income | ¥3,266,000 | ¥4,519,000 | ¥3,121,000 | ¥3,590,000 |
| % Margin | 13.8% | 20.4% | 13.8% | 15.5% |
| EPS | 78.76 | 107.87 | 72.91 | 82.99 |
| % Growth | -27% | 47.9% | -12.1% | – |
| EPS Diluted | 78.76 | 107.87 | 72.91 | 82.99 |
| Weighted Avg Shares Out | 41,453 | 41,892 | 42,805 | 43,272 |
| Weighted Avg Shares Out Dil | 41,453 | 41,892 | 42,805 | 43,272 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥37,000 | ¥25,000 | ¥24,000 | ¥13,000 |
| Interest Expense | ¥7,000 | ¥6,000 | ¥6,000 | ¥6,000 |
| Depreciation & Amortization | ¥1,166,000 | ¥1,153,750 | ¥1,160,000 | ¥1,173,000 |
| EBITDA | ¥4,837,000 | ¥3,262,750 | ¥5,204,000 | ¥5,593,000 |
| % Margin | 20.5% | 14.7% | 23% | 24.1% |